ImmunoPrecise Antibodies (IPA) Stock Statistics & Valuation Metrics

ImmunoPrecise Antibodies has a market cap or net worth of $92.31M. The enterprise value is $22.20M.

ImmunoPrecise Antibodies has 46,154,118 shares outstanding. The number of shares has decreased by -2.65% in one year.

ImmunoPrecise Antibodies’s return on equity (ROE) is -1.28 and return on invested capital (ROIC) is -28.87%.

The current PE Ratio of ImmunoPrecise Antibodies is ―. ImmunoPrecise Antibodies’s PEG ratio is ―.

In the last 12 months, ImmunoPrecise Antibodies had revenue of 24.52M and earned -30.23M in profits. Earnings per share was -0.91.

In the last 12 months, operating cash flow was -7.70M and capital expenditures -1.67M, giving a free cash flow of -9.37M billion.

ImmunoPrecise Antibodies pays an annual dividend of ―, resulting in a dividend yield of ―

ImmunoPrecise Antibodies upcoming earnings date is Sep 11, 2025, TBA (Confirmed).

ImmunoPrecise Antibodies as a current ratio of 2.08, with Debt / Equity ratio of 56.73%

In the past 12 months, ImmunoPrecise Antibodies has paid -4.03M in taxes.

ImmunoPrecise Antibodies EV to EBITDA ratio is -0.79, with an EV/FCF ratio of -3.18.

ImmunoPrecise Antibodies has $12.91M in cash and marketable securities with $12.93M in debt, giving a net cash position of $13.00K billion.

Gross margin is 55.25%, with operating margin of -49.74%, and net profit margin of -123.30%.

The average price target for ImmunoPrecise Antibodies is $3.33, which is 11.43% higher than the current price. The consensus rating is Moderate Buy